276 related articles for article (PubMed ID: 21487803)
1. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis.
Liebl J; Weitensteiner SB; Vereb G; Takács L; Fürst R; Vollmar AM; Zahler S
J Biol Chem; 2010 Nov; 285(46):35932-43. PubMed ID: 20826806
[TBL] [Abstract][Full Text] [Related]
3. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5.
Sharma MR; Tuszynski GP; Sharma MC
J Cell Biochem; 2004 Feb; 91(2):398-409. PubMed ID: 14743398
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro.
Zahler S; Liebl J; Fürst R; Vollmar AM
Angiogenesis; 2010 Sep; 13(3):239-49. PubMed ID: 20706783
[TBL] [Abstract][Full Text] [Related]
5. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
6. Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis.
de Nigris F; Mancini FP; Schiano C; Infante T; Zullo A; Minucci PB; Al-Omran M; Giordano A; Napoli C
J Cell Physiol; 2013 Apr; 228(4):846-52. PubMed ID: 23042366
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitor roscovitine inhibits kinase activity, cell proliferation, multicellular development, and Cdk5 nuclear translocation in Dictyostelium discoideum.
Huber RJ; O'Day DH
J Cell Biochem; 2012 Mar; 113(3):868-76. PubMed ID: 22234985
[TBL] [Abstract][Full Text] [Related]
8. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
12. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.
Berberich N; Uhl B; Joore J; Schmerwitz UK; Mayer BA; Reichel CA; Krombach F; Zahler S; Vollmar AM; Fürst R
Br J Pharmacol; 2011 Jul; 163(5):1086-98. PubMed ID: 21391976
[TBL] [Abstract][Full Text] [Related]
13. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
14. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
15. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells.
Wu PC; Tai MH; Hu DN; Lai CH; Chen YH; Wu YC; Tsai CL; Shin SJ; Kuo HK
J Ocul Pharmacol Ther; 2008 Feb; 24(1):25-33. PubMed ID: 18370874
[TBL] [Abstract][Full Text] [Related]
19. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
Int J Cancer; 2002 Dec; 102(5):463-8. PubMed ID: 12432547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
